2017
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
Callahan MK, Kluger H, Postow MA, Segal NH, Lesokhin A, Atkins MB, Kirkwood JM, Krishnan S, Bhore R, Horak C, Wolchok JD, Sznol M. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. Journal Of Clinical Oncology 2017, 36: jco.2017.72.285. PMID: 29040030, PMCID: PMC5946731, DOI: 10.1200/jco.2017.72.2850.Peer-Reviewed Original ResearchConceptsPhase I dose-escalation studyTreatment-related adverse eventsI dose-escalation studyDose-escalation studyAdvanced melanomaOverall survivalAdverse eventsOS ratesClinical activityGrade 3Common grade 3Doses of nivolumabDurable clinical activityModified WHO criteriaNivolumab Plus IpilimumabTreatment-related deathsUntreated advanced melanomaImmune checkpoint inhibitorsMedian overall survivalObjective response rateLong-term followSubsequent clinical developmentConcurrent nivolumabCheckpoint inhibitorsExpansion cohortPhase I Trial of Triapine–Cisplatin–Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers
Kunos CA, Chu E, Makower D, Kaubisch A, Sznol M, Ivy SP. Phase I Trial of Triapine–Cisplatin–Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers. Frontiers In Oncology 2017, 7: 62. PMID: 28421163, PMCID: PMC5378786, DOI: 10.3389/fonc.2017.00062.Peer-Reviewed Original ResearchCombination regimenSolid tumor cancersI trialTumor cancersAdvanced stageRecurrent uterine cervix cancerCommon grade 3Phase II trialProgression-free survivalPhase I trialContinuous intravenous infusionUterine cervix cancerStable diseaseElectrolyte abnormalitiesII trialObjective responsePaclitaxel chemotherapyReversible anemiaIntravenous infusionMonths durationCervix cancerGrade 3Day 1Day 3Regimen
2012
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. The Lancet Oncology 2012, 13: 459-465. PMID: 22456429, DOI: 10.1016/s1470-2045(12)70090-6.Peer-Reviewed Original ResearchConceptsBrain metastasesCohort ACohort BSerum aspartate aminotransferaseDisease controlIntravenous ipilimumabAdverse eventsAdvanced melanomaCohort B.Common grade 3 adverse eventsAspartate aminotransferaseGrade 3 adverse eventsCommon grade 3Drug-related complicationsPhase 2 trialProportion of patientsUnexpected toxic effectsBristol-Myers SquibbStable diseaseCorticosteroid treatmentPrimary endpointStable dosePartial responseWeek 24Complete response